Loading…

Real-time in-vivo dosimetry for DaRT

Diffusing alpha-emitters radiation therapy (DaRT) is a revolutionary brachytherapy technique used to treat solid tumours. Implant seeds are coated with 224Ra which, along its shortlived daughter atoms, emits alpha particles of high linear energy transfer (LET) and of high relative biological efficie...

Full description

Saved in:
Bibliographic Details
Published in:Journal of physics. Conference series 2020-10, Vol.1662 (1), p.12031
Main Authors: Su, Fang-Yi, Tran, Linh T, Biasi, Giordano, Petasecca, Marco, Lerch, Michael L F, Cutajar, Dean L, Bucci, Joseph, Jackson, Michael, Rosenfeld, Anatoly B
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diffusing alpha-emitters radiation therapy (DaRT) is a revolutionary brachytherapy technique used to treat solid tumours. Implant seeds are coated with 224Ra which, along its shortlived daughter atoms, emits alpha particles of high linear energy transfer (LET) and of high relative biological efficiency (RBE), creating a tumour-killing dose distribution a few mm wide. Those alpha particles are of energy between 5.67 and 8.78 MeV. DaRT is under investigation in clinical trials, but there currently is no obvious solution for dosimetry aimed at quality assurance of treatment. This study introduces alpha-RAD, a dosimeter based on a metal-oxide-semiconductor (MOS) sensor technology. Alpha-RAD was characterized with 241Am, which emits alpha particles of energy 5.49 MeV. The results showed that alpha-RAD had good linearity with dose, with the signal increasing linearly in the range from 0 to 6.84 Gy. Also, an external bias in the range between 15 and 60 V, applied on the gate of alpha-RAD during irradiation, would optimize sensitivity to alpha particles of energies typical of DaRT. Alpha-RAD, owing to its compactness, can fit into a brachytherapy needle, to be placed next to 224Ra seed implants in the tumour, for real-time in vivo dosimetry.
ISSN:1742-6588
1742-6596
DOI:10.1088/1742-6596/1662/1/012031